Method and composition for treating cystic fibrosis

Details Method and composition for treating cystic fibrosis Method and composition for treating cystic fibrosis

1995-01-26

1997-02-11

Cintins, Marianne M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514263, 514264, 514267, 514315, 514334, 514851, 424 45, A61K 3170, A61K 3152, A61K 31445, A61K 3144

Patent

active

056021100

ABSTRACT:
A method and composition for treating cystic fibrosis comprising administering to a patient a first component, a second component, and preferably a third component. The first component is an inhibitor which is specific for a cGMP-inhibited type III cAMP phosphodiesterase, preferably milrinone or amrinone; the second component is an adenylate cyclase activator, preferably forskolin, isoproterenol or albuterol; the third component is cAMP or a cAMP analog which activates protein kinase A.

REFERENCES:
patent: 4501729 (1985-02-01), Boucher et al.
patent: 4851586 (1989-07-01), Bundy et al.
patent: 4866072 (1989-09-01), Edwards et al.
patent: 4939169 (1990-07-01), Bundy et al.
patent: 5006343 (1991-04-01), Benson et al.
patent: 5096916 (1992-03-01), Skupin et al.
patent: 5100647 (1992-03-01), Agus et al.
patent: 5110819 (1992-05-01), Ahnfelt-Ronne et al.
patent: 5140012 (1992-08-01), McGovern et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5250286 (1993-10-01), Skupin et al.
patent: 5279823 (1994-01-01), Frenz et al.
patent: 5320962 (1994-06-01), Stiles et al.
patent: 5384128 (1995-01-01), Meezan et al.
patent: 5434086 (1995-07-01), Collins et al.
K. Sato and F. Sato, "Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro", Jun., 1984, J. Clin. Invest., vol. 73, pp. 1763-1771.
B. Grubb, E. Lazarowski, M. Knowles, and R. Boucher, "Isobutylmethylaxantine fails to stimulate chloride secretion in cystic fibrosis airway epithelia", 1993, Am. J. Respir. Cell. Mol. Biol., vol. 8, pp. 454-460.
M. L. Drumm, J. Wilkinson, L. S. Smit, R. T. Worrell, T. V. Strong, R. A. Frizzell, D. C. Dawson, and F. S. Collins, "Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes", Dec. 20, 1991, Science, vol. 254, pp. 1797-1799.
W. Dalemans, P. Dalemans, P. Barbry, G. Champigny, S. Jallat, K. Dott, D. Dreyer, R. G. Crystal, A. Pavirani, J. P. Lecocq, M. Lazdunski, "Altered chloride ion channel kinetics associated with the .DELTA.F508 cystic fibrosis mutation", Dec. 19/26, 1991, Nature, vol. 354, pp. 526-528.
K. Ono, et al., "Synergistic Action of Cyclic GMP on Catecholamine-Induced Chloride Current in Guinea-Pig Ventricular Cells", 1992, Journal of Physiology, vol. 453, pp. 647-661.
M. Honda, et al., "Contrasting Effects of Isoproterenol and Phosphodiesterase III Inhibitor on Intracellular Calcium Transients in Cardiac Myocytes from Failing Hearts", Dec. 1994, Clinical and Experimental Pharmacology and Physiology, vol. 21, pp. 1001-1008.

Affiliated with

Also associated with

Rating

Method and composition for treating cystic fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and composition for treating cystic fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treating cystic fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-342101